Stock Market Impact: Strong FY26 earnings (+78% revenue, +108% PAT) likely boost investor sentiment for the listed SME and may drive short‑term share price appreciation.
Listed Companies and Sectors: Highlights robust growth in the pharma/healthcare consumer segment, particularly condom and sexual‑wellness products, potentially benefiting peers.
Investment Flows: No specific measures disclosed; however, demonstrated growth could improve attractiveness for foreign investors in the sector.
Interest Rates, Inflation, and Liquidity: No references to monetary policy or inflation in the release.
Fiscal or Monetary Policy: No fiscal or monetary policy announcements mentioned.
